Teva fits a preference for low-valuation stocks as rates rise, and its chart points to another leg higher. It looks to be breaking out of an ascending triangle toward the $45 area. x.com 

Coupang is too cheap here and offers great risk/reward, with heavy insider buying signaling confidence. Director Neil Mehta bought $138M of stock this week, which @Mr_Derivatives tallies at $158M over three days. It also remained one of Stanley Druckenmiller's biggest holdings last quarter, when he likely added more. x.com  x.com